Weight loss candidate drug nimacimab's safety approved, Skye (SKYE.US) stock price surged by 11%.

On Monday local time, Skye Bioscience (SKYE.US) saw its stock price surge by 11%, thanks to the safety differences between its weight loss candidate drug nimacimab and Novo Nordisk A/S Sponsored ADR Class B (NVO.US). Skye emphasized that its monoclonal antibody nimacimab did not show any neurobehavioral events in Phase I studies, and preclinical studies showed minimal accumulation in the brain. Meanwhile, the Phase II clinical trial data for monlunabant released by Novo Nordisk A/S Sponsored ADR Class B last Friday showed significant weight loss effects but with mild to moderate neurobehavioral and gastrointestinal side effects. Following the announcement, the stock price of Novo Nordisk A/S Sponsored ADR Class B dropped. It is understood that Skye is currently conducting Phase II studies on nimacimab for treating obesity and evaluating the efficacy of the GLP-1/CB1 inhibitor combination. Mid-term weight loss data is expected to be released in the second quarter of 2025, with topline data planned for the fourth quarter of 2025. It is worth noting that the GLP-1R agonist drug evaluated in combination with nimacimab is Novo Nordisk A/S Sponsored ADR Class B's Wegovy (semaglutide). On Monday, the stock price of Novo Nordisk A/S Sponsored ADR Class B dropped by 3%, while Viking Therapeutics (VKTX.US), also dedicated to weight loss drug development, saw a 6% decline in stock price. Meanwhile, the stock price of Structure Therapeutics (GPCR.US) rose over 1% against the trend, thanks to Morgan Stanley's positive evaluation giving the company a buy rating for the first time.